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Abstract
Cornelia de Lange syndrome (CdLS) is a genetically heterogeneous disorder
characterized by growth retardation, intellectual disability, upper limb abnormalities, hirsutism, and characteristic facial features. In this study we explored
the occurrence of intragenic NIPBL copy number variations (CNVs) in a cohort
of 510 NIPBL sequence-negative patients with suspected CdLS. Copy number
analysis was performed by custom exon-targeted oligonucleotide array-comparative genomic hybridization and/or MLPA. Whole-genome SNP array was
used to further characterize rearrangements extending beyond the NIPBL gene.
We identified NIPBL CNVs in 13 patients (2.5%) including one intragenic
duplication and a deletion in mosaic state. Breakpoint sequences in two
patients provided further evidence of a microhomology-mediated replicative
mechanism as a potential predominant contributor to CNVs in NIPBL. Patients
for whom clinical information was available share classical CdLS features
including craniofacial and limb defects. Our experience in studying the frequency of NIBPL CNVs in the largest series of patients to date widens the
mutational spectrum of NIPBL and emphasizes the clinical utility of performing
NIPBL deletion/duplication analysis in patients with CdLS.

doi: 10.1002/mgg3.48

Introduction
Cornelia de Lange syndrome (CdLS [MIM 122470]) is a
multisystem disorder characterized by characteristic facial
features, growth retardation, intellectual disability, limb
reduction defects, hirsutism, and moderate-to-severe neurodevelopmental delay (Kline et al. 1993). There is
marked heterogeneity in the CdLS phenotype. At one end
of the spectrum are individuals with classical CdLS features exhibiting profound growth and neurodevelopmental delay, sometimes accompanied by severe limb defects.
Less severe growth retardation and developmental delay
have been observed in mildly affected individuals. The
prevalence of CdLS is estimated to be 1:10,000 live births,
but the incidence may be underestimated given the existence of undiagnosed individuals with milder phenotypes.

Mutations in the NIPBL gene (MIM 608667) have
been identified in ~60% of classical CdLS patients
(Krantz et al. 2004; Tonkin et al. 2004). NIPBL, located
on chromosome 5p13, encodes for the human ortholog
of Drosophila Nipped-B belonging to the family of chromosomal adherins, which are regulators of chromatin
cohesion and enhancer–promoter communication in Drosophila (Rollins et al. 1999, 2004). Genotype–phenotype
correlation studies have demonstrated that NIPBL mutation-positive patients tend to have a more severe phenotype than mutation-negative patients with truncating
mutations, generally causing a more severe phenotype
than missense mutations based on limb differences,
growth, and cognitive function (Gillis et al. 2004). This
suggests that NIPBL is a dosage-sensitive gene. Recently,
somatic mosaicism of NIPBL mutations has been
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described as a relatively frequent occurrence (Huisman
et al. 2013). Mutations in SMC1A (MIM 300040) and
SMC3 (MIM 606062) account for ~5% of patients with a
milder variant of CdLS (Musio et al. 2006; Deardorff
et al. 2007). More recently, de novo mutations in RAD21
(MIM 614701) and HDAC8 (MIM 300269) have been
identified in individuals with growth retardation, minor
skeletal anomalies, and cognitive and facial features consistent with those caused by mutations in NIPBL (Deardorff et al. 2012a,b). The molecular etiology of the
remaining CdLS cases remains unknown.
While the majority of mutations in Mendelian disorders
are detected by sequence analysis, intragenic deletions and
duplications are becoming an increasingly significant factor
in elucidating the molecular etiology of many of these conditions (Aradhya et al. 2012). The identification of a wide
spectrum of NIPBL mutations has made the molecular
analysis of the NIPBL gene a routine component of the clinical and laboratory evaluation of patients with a suspected
CdLS phenotype. Recent studies have shown that intragenic
deletions in NIPBL are present in ~2–5% of patient with
CdLS (Bhuiyan et al. 2007; Pehlivan et al. 2012; Russo et al.
2012). Thus, the presence of NIPBL copy number changes
has become an important factor to consider in CdLS molecular testing in suspected patients with negative NIPBL
sequencing results. In this study we explored the occurrence
of NIPBL copy number alterations in a cohort of 510 NIPBL
sequence-negative patients referred to our laboratory for
CdLS molecular diagnostic testing. We identified 13 cases
with copy number alterations in the NIPBL gene, including
one intragenic duplication and a deletion in the mosaic
state. The size of this patient group is the largest among similar previously reported studies.

copy number changes in 53 genes including NIPBL. The
array contained 2416 probes spanning the NIPBL gene and
flanking 1-kb upstream and downstream regions with an
average resolution of ~1 probe/80 bp across the entire
NIPBL locus. Genomic DNA samples of the patients and
gender-matched controls were processed and cohybridized
onto microarray slides according to the manufacturer’s recommended procedures (Agilent Technologies). Microarray
images were scanned at 2 lm resolution and the data were
extracted using ImaGene (9.0) and analyzed using the Nexus
software (6.0) (BioDiscovery, Hawthorne, CA). The genomic copy number was defined by analysis of the normalized
log 2 (Cy5/Cy3) ratio average of the CGH signal. Regions
that reached a log 2 threshold of at least 0.32 were considered losses consistent with deletion, and thresholds of at
least 0.26 were considered gains consistent with duplication.

MLPA
Multiplex ligation-dependent probe amplification (MLPA)
analysis was performed using the SALSA P141/P142
MLPA kit (MRC-Holland, Amsterdam, the Netherlands)
in accordance with the manufacturer’s instructions. Ligation products were polymerase chain reaction (PCR)
amplified and resolved on an ABI-3730 genetic analyzer
(Life Technologies, Carlsbad, CA). For quantitative analysis, peak heights of the patient and normal control were
analyzed using GeneMarker Software (Soft Genetics Inc.,
State College, PA). Peak heights outside the range 0.7–1.3
times the control peak height were considered abnormal,
with those below 0.7 representing deletions and those
above 1.3 representing duplications.

Whole-genome microarray

Material and Methods

The patient group consisted of 510 patients with clinical
features consistent with CdLS in whom no NIPBL mutation was identified by sequence analysis in our laboratory.
Genomic DNA was isolated from blood leukocytes on the
AutoGenFlex STAR robotic workstation (Autogen, Holliston, MA) or using the MagNA Pure Compact DNA isolation system (Roche Applied Science, Indianapolis, IN)
according to the manufacturer’s instructions.

Whole-genome array analysis was performed using
Affymetrix CytoScan HD arrays (Affymetrix, Santa Clara,
CA). The CytoScan HD array contains around 2.6 million
probes including 7,50,000 single nucleotide polymorphisms (SNPs) and 1.9 million nonpolymorphic markers.
Whole-genome array analysis was performed according to
the manufacturer’s recommended protocol. Images were
acquired using the GeneChip Scanner 3000 7G and analyzed using Chromosome Analysis Suite (ChAS) 1.2.3
software (Affymetrix). Human genome build 19 was used
for annotation.

Array-CGH

Breakpoint junction sequence analyses

Deletion/duplication analysis of the NIPBL gene was
performed using a high-resolution, exon-targeted 8X60K
array-comparative genomic hybridization (CGH) platform
(Agilent Technologies, Santa Clara, CA) designed to detect

Break-point analysis of Patients 7 and 8 was performed
by PCR primer walking using Taq polymerase and the
Expand Long Template PCR System (Roche Applied Science). PCR primers were designed from the reference

Patient samples
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sequence, GenBank accession number NM_133433, across
the deleted and duplicated regions derived from the
array-CGH and MLPA results assuming the most likely
rearrangements. PCR products were sequenced in both
forward and reverse directions on an ABI 3730 DNA
Analyzer (Life Technologies). Sequences were compared
with the NIPBL reference sequence (NM_133433) using
Mutation Surveyor software version 3.01 (Soft Genetics
Inc.).

Results
In total, 13/510 patients (2.5%) were found to harbor
NIPBL structural variations (Table 1).

NIPBL deletions
Patients 1–3 and 6 had relatively small single- and multiexon intragenic deletions ranging from ~2 to ~5 kb in
size. Patients 9, 10, and 12 were found to have larger
multiexon intragenic NIPBL deletions ranging from ~35
to ~94 kb in size. Patients 4, 5, and 11 had deletions
involving the last coding exon of NIPBL and extending
downstream of the gene. To further characterize the
extent of the deletions in Patients 5 and 11, whole-genome microarray analysis was performed (Fig. 1). In
Patient 5, a 24.4 kb deletion was identified at cytogenetic
band position 5p13.2 that included the terminal region
of NIPBL and extended past the gene into the intergenic

Table 1. NIPBL copy number variations identified by targeted CGH/whole-genome arrays.

Patient

Gender

Genotype (NCBI build 37)

1
2
3
4
5

Female
Male
Male
Female
Male

6
7
8
9
10
11

Female
Female
Female
Female
Female
Male

12
13

Male
Male

chr5:g.(37005025_37005435)_(37007490_37007565)del
chr5:g.(36952230_36952266)_(36956007_36956380)del
chr5:g.(36993420_36993499)_(36997655_36997816)del
chr5:g.(37061350_37062360)_(37066620_?)del
chr5:g.(37061350_37062360)_(37066620_?)del
arr 5p13.2(37,065,152-37,089,599)x1**
chr5:g.(37044305_37044340)_(37049000_37049158)del
chr5:g.(36995835_36995861)_(37004025_37004935)del*
chr5:g.(37015062_37015875)_(37021035_37021455)dup
chr5:g.(36968915_36969370)_(37004450_37005025)del
chr5:g.(36964200_36965948)_(37010235_37010791)del
chr5:g.(36997300_36997336)_(37066620_?)del
arr 5p13.2(36,994,939-37,188,352)x1**
chr5:g.(36900635_36903625)_(36998050_36998150)del
chr5:g.(?_36877675)_(37066620_?)del
arr 5p13.1p13.2(35,232,614-40,365,530)x1**

Included
region

CNV type

Ex
Ex
Ex
Ex
Ex

17–18
2–3
11
46–47
46–47

Deletion
Deletion
Deletion
Deletion
Deletion

Ex
Ex
Ex
Ex
Ex
Ex

35–39
12–14*
23–27
7–16
7–21
12–47

Deletion
Deletion
Duplication
Deletion
Deletion
Deletion

Ex 2–11
Whole gene

Deletion
Deletion

Minimum
size (kb)
2.0
3.7
4.1
4.3
4.3
24.4**
4.7
5.0
5.2
35.1
44.3
69.3
193.4**
94.4
189.0
5.1 (Mb)**

*Deletion in mosaic state.
**Nomenclature/size based on SNP array results. NIPBL RefSeq NM_133433.

Pt_5

Pt_11

Pt_13

Figure 1. Characterization of deletions involving NIPBL by whole-genome microarray analysis in Patients 5, 11, and 13. In Patient 5 (Pt_5), a 24.4 kb
deletion extending from the distal end of NIPBL into the intergenic region was observed. In Patient 11 (Pt_11), a 193.4 kb deletion was detected and
extended to C5orf42. In Patient 13 (Pt_13), the deletion spanned 5.1 Mb and included NIPBL and 22 other genes. The copy number state segments
(red for deletion) and copy number state data are shown for each patient. Genes involved are indicated. Not drawn to scale.
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region (arr 5p13.2(37,065,152-37,089,599)x1). A 193.4 kb
deletion (arr 5p13.2(36,994,939-37,188,352)x1) was
observed in Patient 11 and included exons 12–47 of
NIBPL to exons 22–52 of C5orf42 (NM_023073.3),
transcribed in reverse orientation to NIPBL. Patient 13
had a deletion encompassing the entire NIPBL gene.
Whole-genome microarray analysis revealed that the
deletion spanned ~5.1 Mb and involved NIPBL and 22
other genes at the cytogenetic band position 5p13.1p13.2
(arr 5p13.1p13.2 (35,232,614-40,365,530)x1). No additional DNA was available to further characterize the
extent of the deletion detected in Patient 4.
In addition, a deletion of exons 12–14 in an apparent
mosaic state was found in Patient 7. The array-CGH data
showed low-level reduction in the Cy5/Cy3 fluorescence
log 2 ratio of oligonucleotide probes interrogating exons
11–16 (Fig. 2A). The decreased log 2 (Cy5/Cy3) fluorescence ratios did not reach the lower defined threshold
value of 0.32 and therefore this aberration was not
called by the analysis software. MLPA analysis showed a
~30% decrease in signal intensity for probes specific for
NIPBL exons 12, 13, and 14, supporting the finding of
mosaicism (Fig. 2B). Various combinations of PCR primer pairs were designed to amplify the putative deletion
breakpoint junction based on the array-CGH and MLPA
results. A unique 5 kb PCR product was obtained in the
patient and not in the control when using primers 5′ and
3′ of introns 11 and 14, respectively. Sequence analysis of
the PCR product revealed a 4968 base-pair deletion of
chr5: 36,997,269-37,002,237 that included NIPBL exons
12–14 with a 4-bp microhomology (AGGA) at the breakpoint junction (Fig. 2C). No other tissue was available for
the study.

NIPBL duplications
One novel multiexon NIPBL duplication was also identified in this cohort: a ~5 kb duplication of NIPBL exons
23–27 in Patient 8. The breakpoint junction of the
duplication detected by array-CGH and MLPA (Fig. 3A
and B) was successfully amplified by long-range PCR
using primers positioned at the very end of the duplication breakpoints, as determined by array-CGH, under the
assumption that the repeated copies were arranged in tandem (Fig. 3C). Sequence analysis demonstrated that exons
23–27 were duplicated in tandem and revealed a 7-bp
insertion (ATATAAT) and a 1-bp microhomology (T) at
the breakpoint junction (Fig. 3D). Follow-up MLPA
analysis of the patient’s parents confirmed that the duplication was de novo in the patient.

Phenotypes of CdLS patients with genomic
rearrangements in NIPBL
Clinical information was collected for 10 of the 13
patients with NIPBL deletions/duplications and is presented in Table S1. Information on growth, development,
craniofacial, limb abnormalities, as well as other systemic/
organ involvement was requested. Age of patients ranged
from 1 day to 19 years old. Complete clinical information
was not available for all parameters requested and due to
the young ages (1 day to 3 months) of the majority of
patients, information on intellectual deficiencies and
developmental delay were not fully ascertained. All
reported patients had facial features consistent with CdLS,
regardless of the size or location of their deletion/duplication. All patients on whom information was available had

Figure 2. Break-point analysis of the mosaic deletion of NIPBL exons 12–14 in Patient 7. (A) Array-CGH profile (top) with the magnified region of
interest (bottom) showing low-level reduction in the Cy5/Cy3 fluorescence log 2 ratio of oligonucleotide probes spanning exons 11–16; (B) MLPA
histogram: NIPBL exons arrowed in red (12–14) showing reduced height ratio in comparison with control probes (~0.7 vs. 1); (C) nucleotide
sequence of the break points. Proximal reference sequence and patient break-point sequence that match with the proximal reference sequence
are shown in green, whereas the distal reference sequence and patient break-point sequence that match with the distal reference sequence are
shown in red. Dash boxed sequence corresponds to a region of microhomology and reveals the break-point junction.
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Figure 3. Breakpoint analysis of the duplication of NIPBL exons 23–27 in Patient 8. (A) Array-CGH results revealed a duplication of NIPBL exons
23–27; (B) MLPA histogram: NIPBL exons arrowed in red (23–27) showing increased height ratio (~1.4 vs. 1); (C) schematic diagram of the
duplicated region with dashed square boxes representing the exons duplicated in tandem. Arrow heads indicate the location of PCR primers used
to amplify the breakpoint junction of the duplication; (D) Nucleotide sequence of the breakpoint revealing insertion (purple) of seven nucleotides
(ATATAAT) and 1bp-microhomology (dash box) at the breakpoint junction; (E) Photo of Patient 8 taken at two weeks of age.

a thin upper lip, long smooth philtrum, upturned nares,
and all but one had synophyrs and long thick eyelashes.
All reported patients had characteristic limb abnormalities
ranging from mild (fifth finger clinodactyly and 2–3 toe
syndactyly) to severe (monodactyly and missing forearms). Other recurrent systems affected included cardiovascular defects, hearing loss, genitourinary anomalies,
and gastroesophageal reflux, all of which are features seen
in patients with CdLS.

Discussion
We identified 13 copy number variations (CNVs) in a
cohort of 510 CdLS cases. Copy number analysis was per-

formed utilizing high-density array-CGH targeted to the
NIPBL gene, whole-genome SNP array, and MLPA. Deletions were found to be more common, with 12 deletions
and 1 duplication identified. The CNVs ranged in size
from 2 kb to 5.1 Mb with the minimum affecting one
exon to the maximum affecting NIPBL and other adjacent
genes at 5p13 (Fig. 4).
The CNVs identified in this study appear to not have
been previously described in the literature supporting the
broad allelic heterogeneity of NIPBL mutations in CdLS.
An exception could be possibly represented by the 4.1 kb
deletion of exon 11 observed in Patient 3 as a deletion
similar in size and location has been reported previously
(Pehlivan et al. 2012), and the apparently similar deletions

ª 2013 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals, Inc.
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Figure 4. Schematic diagram of the NIPBL gene displaying exonic deletions and duplications in 13 patients. On top: graphic view of 47 exons
(vertical blue bars) of NIPBL: solid horizontal bars represent NIPBL genomic regions deleted (red) or duplicated (green) and approximate sizes. The
deletion in mosaic state in Patient 7 is indicated by a striped red bar. Narrow dotted bars indicate rearrangements extending beyond the gene in
Patients 4, 5, 11, and 13. The graphical data for each patient were obtained by inputting the most distal and proximal oligonucleotide genomic
probe coordinates into the custom track at the University of California, Santa Cruz website: http://genome.ucsc.edu/cgi-bin/hgGateway.

of exons 46 and 47 identified in Patients 4 and 5. Interestingly, comparison of the sequences flanking the break
points, based on array-CGH coordinates in our Patient 3
and sequence information available for the previously
reported patient, revealed the presence of Alu sequences
with ~80% sequence similarity (AluY and AluJo) in the
proximity of the borders of both deletions. Moreover, an
enrichment of repetitive elements (AluJb and AluSq2) and
MER2 DNA elements was also noted in the region of
intron 45 (chr5: 37061350–37062360) containing the
proximal breakpoint of the exons 46–47 deletions found
in Patients 4 and 5. As previously suggested (Stankiewicz
et al. 2003; Lupski 2007), it is possible that repetitive elements may play a role in predisposing some of these NIPBL regions to structural instability, although whether these
motifs have any mechanistic role in the formation of some
NIPBL deletions has yet to be determined.
Partial NIPBL gene deletions extending beyond the 5′
end of the gene were observed in Patients 4, 5, and 11.
Whole-genome microarray analysis performed in Patients
5 and 11 (no additional DNA was available for Patient
4) revealed that the deletion in Patient 11 included the
terminal part of the C5orf42 gene. Point mutations of
the C5orf42 gene have recently been associated with
autosomal recessive Joubert syndrome (Srour et al.
2012). As Joubert syndrome is a recessively inherited
multisystemic disorder, we feel that its involvement in
this deletion is unlikely to contribute to this patient’s
phenotype.
A large deletion involving the entire NIPBL gene was
identified in Patient 13. This deletion spans ~5 Mb in the
5p13.1-13.2 region and encompasses NIPBL and 22 other
genes as indicated by whole-genome SNP array analysis.
Physical examination of Patient 13 showed the presence of
the classical craniofacial features of CdLS, bilateral upper
limb reduction, genital abnormalities, bilateral hydroneph-
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rosis, Dandy Walker malformation, and developmental
delay. The complexity of this patient’s phenotype can be
attributed to the combined haploinsufficiency of dosagesensitive genes located within the deletion; however, the
fact that the patient has classic CdLS features suggests that
NIPBL is the major dosage-sensitive gene. Large deletions
involving the NIPBL gene have been reported previously,
and while phenotypic heterogeneity exists between patients,
all display minimally diagnostic features of CdLS (Russo
et al. 2012; Gervasini et al. 2013b).
Somatic mosaicism has previously been described in
patients with CdLS and is not an uncommon occurrence
in the mutational landscape of the NIPBL gene (Huisman
et al. 2013). The array-CGH and MLPA data of mild-tomedium probe signal reductions infer the mechanism of
somatic mosaicism for a deletion involving exons 12–14
in Patient 7. Breakpoint sequence analysis confirmed the
presence of the deletion and revealed a 4-bp microhomology at the break-point junction consistent with a possible
replicative mechanism such as FoSTes/microhomologymediated break-induced replication as previously suggested (Pehlivan et al. 2012). A case of somatic mosaicism
for a frameshift mutation in NIPBL has been reported
previously in a patient showing a phenotype milder than
that predicted by a truncating mutation (Castronovo
et al. 2010). More recently, high level of mosaicism for a
large deletion encompassing exons 2–32 of the NIPBL
gene was identified in a patient with severe CdLS phenotype (Gervasini et al. 2013a). Our patient demonstrates
typical CdLS facial features, but no severe limb reduction
defects or other major abnormalities. The clinical phenotype of Patient 7 was comparable with other NIPBL deletion patients and was reported to be “classic CdLS” by
the referring physician. A caveat is that the clinical examination of Patient 7 was done at 3 months of age; therefore, the cognitive and developmental information was
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limited and additional follow-up of the patient was not
performed. Other tissues were not available for study and
therefore we cannot exclude that the levels of somatic
mosaicism might be higher in other tissues, thus leading
to further functional impairments.
Intragenic duplications in the NIPBL gene appear to be
rarer than deletions, with only one other patient harboring a single-exon duplication being reported recently
(Russo et al. 2012). In this study, we identified a previously unreported de novo duplication of NIPBL exons
23–27 in Patient 8. Breakpoint analysis revealed the presence of a 7-bp insertion flanked by 1-bp microhomology,
again suggesting a microhomology-mediated replicative
mechanism as a potential predominant contributor to this
rearrangement. No clinical information was available for
the patient reported by Russo et al. (2012) with a duplication of exon 32 to compare with our duplication
patient. 5q13 duplication syndrome [MIM#613174] is
generally considered a distinct phenotype than the one
observed in CdLS patients, and recently Novara et al.
(2013) reported a patient with a 5p13 duplication including the NIPBL gene only and observed overlapping features with 5p13 microduplication syndrome. The
phenotype of Patient 8 did not diverge dramatically from
the classic CdLS spectrum. The patient’s characteristic
CdLS features included synophyrs, hirsutism, low posterior hairline, flat nasal bridge and upturned nose, thin
upper lip, and downturn corners of the mouth (Fig. 3E).
While 5p13 microduplication patients present with long
fingers, large hands and feet, Patient 8 had small fingers
and hands, and complete 2–3 toe syndactyly. In addition,
Patient 8 had complete, unbalanced AV canal with hypoplastic left heart, and whereas congenital heart malformations occur in 25% of patients with CdLS, none have
been reported to date in patients with 5p13 microduplication syndrome. The exons 23–27 duplication in Patient 8
is predicted to result in an out-of-frame protein and is a
plausible cause of the patient’s CdLS phenotype.
As CdLS is a well-described multiple malformation syndrome, we compared several CdLS facial features in our
patient group with previously reported patients with NIPBL point mutations (Table S1). All patients for whom
information was available shared the characteristic facial
features of CdLS, including thin upper lip, long smooth
philtrum, upturned nares, and all but one had synophyrs
and long thick eyelashes. These facial features are the clinical hallmark of CdLS with synophyrs in 98%, long thick
eyelashes in 99%, thin upper lip in 94%, and upturned
nares in 85% of affected individuals (Kline et al. 2007).
Cleft palate, which was identified in 2/7 (29%) of patients
in our study, is seen in ~20% of patients with CdLS
(Kline et al. 2007). No significant differences were identified in the presence of these features in our patients with

NIPBL CNVs and in patients with NIPBL point mutations
(Borck et al. 2007; Schoumans et al. 2007).
Previous studies analyzing genotype–phenotype correlation in mutation-positive cases have suggested that
patients with missense mutations are associated with
milder phenotypes than those with truncating mutations
(Gillis et al. 2004). Thus, we have further explored the
possible genotype–phenotype correlation in our patient
cohort. The majority of our patient cohort fell within the
moderate-to-mild range (Table S2). Some correlation can
be seen with regards to the size of deletion and severity
of growth retardation. Patients with larger multiexonic
deletions, like Patient 11 (69 kb deletion), had severe
growth retardation, and patients with smaller single-exon
deletions, like Patient 3 (4.1 kb deletion), had mild
growth retardation. The severity pattern of limb reduction
defects of our patient cohort is also similar and more in
line with missense mutation patients (Table S2). One
explanation of this is that several of our intragenic deletion cases (Patient 1, Patient 3, and Patient 7), which correlated with mild limb reduction defects, are predicted to
result in in-frame deletions that may still lead to the formation of a NIPBL protein with some residual function.
In addition, Patient 2, who also had mild limb reduction
defects, has a deletion of exons 2–3. As exon 2 contains
the primary start codon, it is possible that a downstream
start codon at c.334 in exon 4 may possibly be utilized to
initiate protein translation. While the deletion in Patient
6 is predicted to result in an out-of-frame deletion, the
milder limb defects observed in this patient could be
related to the smaller size of this patient’s deletion and
potentially to some functional aspect of the protein being
preserved due to its more distal location within the gene.
The large size of the deletions in Patients 9, 10, and 13
correlate with greater upper limb involvement and is consistent with the proposal that phenotypic severity is proportional to number of exons involved (Pehlivan et al.
2012). Other modifying factors, either at the NIPBL locus
or at other genomic sites, may also play a role in the
severity of limb reduction defects. Importantly, as all but
three of our patients were 3 months old or younger, the
lack of information regarding cognitive function is likely
due to the inability to make such evaluations at the time
of assessment.
In this study we further documented the heterogeneity
of NIPBL genomic rearrangements in a cohort of 510
sequence-negative CdLS cases and identified NIPBL copy
number aberrations in 13 (2.5%) unrelated patients. Our
detection rate is lower than previously described studies,
which identified NIPBL structural rearrangements in ~5%
of mutation-negative patients (Pehlivan et al. 2012; Russo
et al. 2012). This is potentially explained by the wide phenotypic variability of patients sent to our laboratory for
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NIPBL analysis for diagnostic testing purposes. Our detection rate likely represents the true mutation detection rate
of NIPBL copy number changes in the clinical setting.
In summary, we have shown that intragenic NIPBL
deletion/duplication events are not uncommon in CdLS
patients and result in a similar phenotype to patients with
NIPBL point mutations. Our data contribute additional
information regarding the NIPBL mutation spectrum in
CdLS and emphasize the utility of NIPBL deletion and
duplication analysis in the molecular diagnosis of CdLS,
especially in the absence of identifiable NIPBL point
mutations.
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Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Table S1. Clinical features of 10 patients with copy number variations in NIPBL. The final column summarizes
the facial features of CdLS patients identified with point
mutations in NIBPL in comparison with the facial features of our patient cohort (second to last column).
Table S2. Limb reduction defect and growth retardation
correlation of NIPBL copy number changes found in
CdLS patients in our study.
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